血管紧张素受体阻滞剂的多效性作用
The pleiotropic effects of angiotensin receptor blockers.
作者信息
Chrysant Steven G, Chrysant George S
机构信息
Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, 5850 West Wilshire Boulevard, Oklahoma City, OK 73132-4904, USA.
出版信息
J Clin Hypertens (Greenwich). 2006 Apr;8(4):261-8. doi: 10.1111/j.1524-6175.2005.05264.x.
Abstract
The angiotensin receptor blockers (ARBs) are very effective and safe antihypertensive drugs. They exert their antihypertensive effect through blockage of the angiotensin II, type 1 receptor and quite possibly through stimulation by angiotensin II of the unoccupied type 2 receptor. Besides hypertension, the ARBs have been found recently to be of value in the treatment of heart failure and diabetic nephropathy. In addition, ARBs have emerged lately as being very effective and perhaps superior to other antihypertensive drugs in the prevention of de novo or recurrent strokes. Other actions that may account for their stroke-protective effects include their antiatherogenic, antidiabetic, antiplatelet aggregating, hypouricemic, and atrial antifibrillatory actions. All these actions make the ARBs a true pleiotropic class of drugs. Each of the foregoing effects will be discussed briefly in this concise review.
摘要
血管紧张素受体阻滞剂（ARBs）是非常有效且安全的抗高血压药物。它们通过阻断血管紧张素II 1型受体发挥抗高血压作用，很可能还通过血管紧张素II对未被占据的2型受体的刺激作用来实现。除高血压外，最近发现ARBs在治疗心力衰竭和糖尿病肾病方面具有价值。此外，ARBs最近已成为预防新发或复发性中风非常有效且可能优于其他抗高血压药物的药物。其他可能解释其对中风保护作用的作用包括其抗动脉粥样硬化、抗糖尿病、抗血小板聚集、降尿酸和心房抗纤颤作用。所有这些作用使ARBs成为一类真正具有多效性的药物。在这篇简要综述中将简要讨论上述每种作用。
相似文献
1
The pleiotropic effects of angiotensin receptor blockers.
J Clin Hypertens (Greenwich). 2006 Apr;8(4):261-8. doi: 10.1111/j.1524-6175.2005.05264.x.
2
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Cardiovasc Diabetol. 2013 Nov 4;12:159. doi: 10.1186/1475-2840-12-159.
3
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int. 2005 Oct;14(79):180-6.
4
The impact of suppressing the renin-angiotensin system on atrial fibrillation.
J Clin Pharmacol. 2006 Jan;46(1):21-8. doi: 10.1177/0091270005283284.
5
Valsartan and recurrent atrial fibrillation.
N Engl J Med. 2009 Jul 30;361(5):532-3; author reply 533.
6
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Postgrad Med. 2001 Apr;109(4):115-22; quiz 9. doi: 10.3810/pgm.2001.04.911.
7
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Pharmacol Res. 2002 Sep;46(3):203-12. doi: 10.1016/s1043-6618(02)00092-0.
8
Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
J Clin Hypertens (Greenwich). 2004 Aug;6(8):445-51. doi: 10.1111/j.1524-6175.2004.03449.x.
9
Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.
J Hum Hypertens. 2005 Dec;19(12):923-31. doi: 10.1038/sj.jhh.1001916.
10
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
J Clin Hypertens (Greenwich). 2011 Nov;13(11):801-12. doi: 10.1111/j.1751-7176.2011.00539.x. Epub 2011 Oct 18.
引用本文的文献
1
Angiotensin II and Atherosclerosis: A New Cardiovascular Risk Factor Beyond Hypertension.
Int J Mol Sci. 2025 Aug 4;26(15):7527. doi: 10.3390/ijms26157527.
2
ACEi and ARBs as Primary Prevention of Cancer Therapy-Related Cardiomyopathy in Patients Undergoing Chemotherapy with Anthracyclines: A Systematic Review and Meta-Analysis.
Cardiol Ther. 2025 Jun;14(2):141-159. doi: 10.1007/s40119-025-00401-z. Epub 2025 Mar 16.
3
Unveiling Wide Spectrum Therapeutic Implications and Signaling Mechanisms of Valsartan in Diverse Disorders: A Comprehensive Review.
Curr Drug Res Rev. 2024;16(3):268-288. doi: 10.2174/2589977515666230717120828.
4
Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real-world database: A retrospective cohort study.
Health Sci Rep. 2023 Jan 31;6(2):e1056. doi: 10.1002/hsr2.1056. eCollection 2023 Feb.
5
Fimasartan Ameliorates Deteriorations in Glucose Metabolism in a High Glucose State by Regulating Skeletal Muscle and Liver Cells.
Yonsei Med J. 2022 Jun;63(6):530-538. doi: 10.3349/ymj.2022.63.6.530.
6
Gastroprotective Effect of Azilsartan Through Ameliorating Oxidative Stress, Inflammation, and Restoring Hydroxyproline, and Gastrin Levels in Ethanol-Induced Gastric Ulcer.
J Inflamm Res. 2022 May 11;15:2911-2923. doi: 10.2147/JIR.S365090. eCollection 2022.
7
Comparative Study of the Effects of Azilsartan and Telmisartan on Insulin Resistance and Metabolic Biomarkers in Essential Hypertension Associated With Type 2 Diabetes Mellitus.
Cureus. 2022 Feb 16;14(2):e22301. doi: 10.7759/cureus.22301. eCollection 2022 Feb.
8
CoQ10 augments candesartan protective effect against tourniquet-induced hind limb ischemia-reperfusion: Involvement of non-classical RAS and ROS pathways.
Saudi Pharm J. 2021 Jul;29(7):724-733. doi: 10.1016/j.jsps.2021.05.004. Epub 2021 May 20.
9
Oxidative Stress in Ischemic Heart Disease.
Oxid Med Cell Longev. 2020 Dec 28;2020:6627144. doi: 10.1155/2020/6627144. eCollection 2020.
10
Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration.
Yonsei Med J. 2019 Jul;60(7):679-686. doi: 10.3349/ymj.2019.60.7.679.
本文引用的文献
1
Angiotensin receptor blockers and risk of myocardial infarction: systematic review.
BMJ. 2005 Oct 15;331(7521):873. doi: 10.1136/bmj.38595.518542.3A. Epub 2005 Sep 23.
2
How to explain the differences between renin angiotensin system modulators.
Am J Hypertens. 2005 Sep;18(9 Pt 2):134S-141S. doi: 10.1016/j.amjhyper.2005.05.005.
3
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.
Am J Med Sci. 2005 May;329(5):222-7. doi: 10.1097/00000441-200505000-00002.
4
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke. 2005 Jun;36(6):1218-26. doi: 10.1161/01.STR.0000166048.35740.a9. Epub 2005 May 5.
5
Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.
Hypertension. 2005 May;45(5):880-6. doi: 10.1161/01.HYP.0000161880.59963.da. Epub 2005 Apr 4.
6
Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age.
Hypertension. 2005 May;45(5):840-4. doi: 10.1161/01.HYP.0000159192.93968.8f. Epub 2005 Feb 28.
7
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
J Am Coll Cardiol. 2005 Mar 1;45(5):712-9. doi: 10.1016/j.jacc.2004.10.068.
8
Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan.
J Hum Hypertens. 2005 Mar;19(3):173-83. doi: 10.1038/sj.jhh.1001808.
9
Angiotensin II and the endothelium: diverse signals and effects.
Hypertension. 2005 Feb;45(2):163-9. doi: 10.1161/01.HYP.0000153321.13792.b9. Epub 2005 Jan 3.
10
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
J Hypertens. 2004 Dec;22(12):2253-61. doi: 10.1097/00004872-200412000-00003.
Zotero 插件